Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients

Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients

Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of T2DM; some SGLT2i have reported a CV benefit and some reported a risk of BKA. U.S. claims databases were analyzed using a prespecified protocol to examine CANA-associated effects on BKA and hospitalization for heart f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: RYAN, PATRICK, BUSE, JOHN B., SCHUEMIE, MARTIJN, DEFALCO, FRANK, YUAN, ZHONG, STANG, PAUL, BERLIN, JESSE A., ROSENTHAL, NORM
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 67
creator RYAN, PATRICK
BUSE, JOHN B.
SCHUEMIE, MARTIJN
DEFALCO, FRANK
YUAN, ZHONG
STANG, PAUL
BERLIN, JESSE A.
ROSENTHAL, NORM
description Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of T2DM; some SGLT2i have reported a CV benefit and some reported a risk of BKA. U.S. claims databases were analyzed using a prespecified protocol to examine CANA-associated effects on BKA and hospitalization for heart failure (HHF) vs. other SGLT2i and non-SGLT2i. Analyses used a propensity score adjusted new user design with numerous sensitivity analyses. The 4 databases included 142K new users of CANA, 110K of other SGLT2i, and 460K of non-SGLT2i AHAs. Meta-analysis results are reported when heterogeneity across databases was not substantial (I2
doi_str_mv 10.2337/db18-4-LB
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db18_4_LB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db18_4_LB</sourcerecordid><originalsourceid>FETCH-LOGICAL-c74B-bd6dded7e01c9948ace1403c6d6e3b8cff2de6f4952859e5a8ab9565275237533</originalsourceid><addsrcrecordid>eNo9kE1OwzAQhS0EEqWw4AZethIOdpzE8QYpKb9qoKgUwS5yHKc1pEllB6qw4hDcgltxElJAaBYjjd775ukBcEiw41LKjvOMhMhDSbwFeoRTjqjLHrdBD2PiIsI42wV71j5hjINueuBzJCoxL3VR1m-6goNRdBMN4at14KRZKAOjqtGLdqXMvGylWmoJo7mqGgvrCnYCONX2GdYFjFVZr9G4UgpGy9VLIxrdKQbxuKMVtYG33eHHt9bNAs7c0-uv948ITpUo0UNtyrz7JMrWaruhnTCMj7qM8N65c_69-2CnEKVVB3-7D2bnZ7PRJUomF1ejKEGSeTHK8iDPVc4UJpJzLxRSEQ9TGeSBolkoi8LNVVB43HdDnytfhCLjfuC7zHcp8yntg-EvVpraWqOKdGX0Upg2JTjdlJxuSk69NInpN3srby8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of &gt;700,000 U.S. Patients</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>RYAN, PATRICK ; BUSE, JOHN B. ; SCHUEMIE, MARTIJN ; DEFALCO, FRANK ; YUAN, ZHONG ; STANG, PAUL ; BERLIN, JESSE A. ; ROSENTHAL, NORM</creator><creatorcontrib>RYAN, PATRICK ; BUSE, JOHN B. ; SCHUEMIE, MARTIJN ; DEFALCO, FRANK ; YUAN, ZHONG ; STANG, PAUL ; BERLIN, JESSE A. ; ROSENTHAL, NORM</creatorcontrib><description>Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of T2DM; some SGLT2i have reported a CV benefit and some reported a risk of BKA. U.S. claims databases were analyzed using a prespecified protocol to examine CANA-associated effects on BKA and hospitalization for heart failure (HHF) vs. other SGLT2i and non-SGLT2i. Analyses used a propensity score adjusted new user design with numerous sensitivity analyses. The 4 databases included 142K new users of CANA, 110K of other SGLT2i, and 460K of non-SGLT2i AHAs. Meta-analysis results are reported when heterogeneity across databases was not substantial (I2 &lt;0.4). There was no evidence of increased risk of BKA with CANA vs. non-SGLT2i or other SGLT2i in on-treatment or ITT analyses (Table). HHF benefits were demonstrated in these analyses, consistent with clinical trials. Similar BKA and HHF results were seen in a subgroup with established CV disease. In this large comprehensive analysis, neither CANA nor other SGLT2i showed an increased risk of amputation vs. non-SGLT2i. Because on-treatment median exposure was &lt;6 months, future observational studies with longer duration are needed. This study helps to further characterize the potential benefits and harms of SGLT2i as observed in routine clinical practice to complement the evidence from clinical trials and prior observational studies.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-4-LB</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c74B-bd6dded7e01c9948ace1403c6d6e3b8cff2de6f4952859e5a8ab9565275237533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>RYAN, PATRICK</creatorcontrib><creatorcontrib>BUSE, JOHN B.</creatorcontrib><creatorcontrib>SCHUEMIE, MARTIJN</creatorcontrib><creatorcontrib>DEFALCO, FRANK</creatorcontrib><creatorcontrib>YUAN, ZHONG</creatorcontrib><creatorcontrib>STANG, PAUL</creatorcontrib><creatorcontrib>BERLIN, JESSE A.</creatorcontrib><creatorcontrib>ROSENTHAL, NORM</creatorcontrib><title>Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of &gt;700,000 U.S. Patients</title><title>Diabetes (New York, N.Y.)</title><description>Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of T2DM; some SGLT2i have reported a CV benefit and some reported a risk of BKA. U.S. claims databases were analyzed using a prespecified protocol to examine CANA-associated effects on BKA and hospitalization for heart failure (HHF) vs. other SGLT2i and non-SGLT2i. Analyses used a propensity score adjusted new user design with numerous sensitivity analyses. The 4 databases included 142K new users of CANA, 110K of other SGLT2i, and 460K of non-SGLT2i AHAs. Meta-analysis results are reported when heterogeneity across databases was not substantial (I2 &lt;0.4). There was no evidence of increased risk of BKA with CANA vs. non-SGLT2i or other SGLT2i in on-treatment or ITT analyses (Table). HHF benefits were demonstrated in these analyses, consistent with clinical trials. Similar BKA and HHF results were seen in a subgroup with established CV disease. In this large comprehensive analysis, neither CANA nor other SGLT2i showed an increased risk of amputation vs. non-SGLT2i. Because on-treatment median exposure was &lt;6 months, future observational studies with longer duration are needed. This study helps to further characterize the potential benefits and harms of SGLT2i as observed in routine clinical practice to complement the evidence from clinical trials and prior observational studies.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kE1OwzAQhS0EEqWw4AZethIOdpzE8QYpKb9qoKgUwS5yHKc1pEllB6qw4hDcgltxElJAaBYjjd775ukBcEiw41LKjvOMhMhDSbwFeoRTjqjLHrdBD2PiIsI42wV71j5hjINueuBzJCoxL3VR1m-6goNRdBMN4at14KRZKAOjqtGLdqXMvGylWmoJo7mqGgvrCnYCONX2GdYFjFVZr9G4UgpGy9VLIxrdKQbxuKMVtYG33eHHt9bNAs7c0-uv948ITpUo0UNtyrz7JMrWaruhnTCMj7qM8N65c_69-2CnEKVVB3-7D2bnZ7PRJUomF1ejKEGSeTHK8iDPVc4UJpJzLxRSEQ9TGeSBolkoi8LNVVB43HdDnytfhCLjfuC7zHcp8yntg-EvVpraWqOKdGX0Upg2JTjdlJxuSk69NInpN3srby8</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>RYAN, PATRICK</creator><creator>BUSE, JOHN B.</creator><creator>SCHUEMIE, MARTIJN</creator><creator>DEFALCO, FRANK</creator><creator>YUAN, ZHONG</creator><creator>STANG, PAUL</creator><creator>BERLIN, JESSE A.</creator><creator>ROSENTHAL, NORM</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180701</creationdate><title>Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of &gt;700,000 U.S. Patients</title><author>RYAN, PATRICK ; BUSE, JOHN B. ; SCHUEMIE, MARTIJN ; DEFALCO, FRANK ; YUAN, ZHONG ; STANG, PAUL ; BERLIN, JESSE A. ; ROSENTHAL, NORM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c74B-bd6dded7e01c9948ace1403c6d6e3b8cff2de6f4952859e5a8ab9565275237533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RYAN, PATRICK</creatorcontrib><creatorcontrib>BUSE, JOHN B.</creatorcontrib><creatorcontrib>SCHUEMIE, MARTIJN</creatorcontrib><creatorcontrib>DEFALCO, FRANK</creatorcontrib><creatorcontrib>YUAN, ZHONG</creatorcontrib><creatorcontrib>STANG, PAUL</creatorcontrib><creatorcontrib>BERLIN, JESSE A.</creatorcontrib><creatorcontrib>ROSENTHAL, NORM</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RYAN, PATRICK</au><au>BUSE, JOHN B.</au><au>SCHUEMIE, MARTIJN</au><au>DEFALCO, FRANK</au><au>YUAN, ZHONG</au><au>STANG, PAUL</au><au>BERLIN, JESSE A.</au><au>ROSENTHAL, NORM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of &gt;700,000 U.S. Patients</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of T2DM; some SGLT2i have reported a CV benefit and some reported a risk of BKA. U.S. claims databases were analyzed using a prespecified protocol to examine CANA-associated effects on BKA and hospitalization for heart failure (HHF) vs. other SGLT2i and non-SGLT2i. Analyses used a propensity score adjusted new user design with numerous sensitivity analyses. The 4 databases included 142K new users of CANA, 110K of other SGLT2i, and 460K of non-SGLT2i AHAs. Meta-analysis results are reported when heterogeneity across databases was not substantial (I2 &lt;0.4). There was no evidence of increased risk of BKA with CANA vs. non-SGLT2i or other SGLT2i in on-treatment or ITT analyses (Table). HHF benefits were demonstrated in these analyses, consistent with clinical trials. Similar BKA and HHF results were seen in a subgroup with established CV disease. In this large comprehensive analysis, neither CANA nor other SGLT2i showed an increased risk of amputation vs. non-SGLT2i. Because on-treatment median exposure was &lt;6 months, future observational studies with longer duration are needed. This study helps to further characterize the potential benefits and harms of SGLT2i as observed in routine clinical practice to complement the evidence from clinical trials and prior observational studies.</abstract><doi>10.2337/db18-4-LB</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db18_4_LB
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
title Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A57%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Canagliflozin%20(CANA)%20vs.%20Other%20Antihyperglycemic%20Agents%20on%20the%20Risk%20of%20Below-Knee%20Amputation%20(BKA)%20for%20Patients%20with%20T2DM%E2%80%94A%20Real-World%20Analysis%20of%20%3E700,000%20U.S.%20Patients&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=RYAN,%20PATRICK&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-4-LB&rft_dat=%3Ccrossref%3E10_2337_db18_4_LB%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true